CCR2 Antagonist from Santa Cruz Biotechnology, Inc.

Product Specs
ItemCCR2 Antagonist
CompanySanta Cruz Biotechnology, Inc.
Price $299.00Supplier Page View Company Product Page
Catalog Numbersc-202525
Quantity5 mg
TypeBiochemical Reagents
Molecular Weight593.7

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Dermal fibroblasts respond to interleukin-4 and 13 and promote T-cell recruitment in atopic dermatitisJournal of Clinical InvestigationMarch 2, 2026Tomofumi Numata, Michael Shia, Yoshiyuki Nakamura, Fengwu Li, Hung Chan, Teruaki Nakatsuji, Kellen J. Cavagnero, Jared Simmons, Henry Li, Aaroh Anand Joshi, et al.inhibitor (BX471, 0.1 μg/mL; HY-12080, MedChemExpress); CCR2 inhibitor (CAS 445479-97-0, 10 μg/mL; sc-202525, Santa Cruz Biotechnology); CCR3 inhibitor (SB-328437, 10 μg/mL; HY-103363, MedChemExpress); CCR4 inhibitor

(2) TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasionCancer lettersOctober 10, 2022Tian Z, Ou G, Su M, Li R, Pan L, Lin X, Zou J, Chen S, Li Y, Huang K, et al.

(3) Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signalingLaboratory investigation; a journal of technical methods and pathologyApril 1, 2022Kang SU, Cho SY, Jeong H, Han J, Chae HY, Yang H, Sung CO, Choi YL, Shin YK, Kwon MJ.

(4) Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytesJournal of experimental & clinical cancer research : CRApril 12, 2021Mattoscio D, Isopi E, Lamolinara A, Patruno S, Medda A, De Cecco F, Chiocca S, Iezzi M, Romano M, Recchiuti A.classical monocyte recruitment in tumors, tumor bearing mice were treated with the CCR2 antagonist SC-202525 (Santa Cruz Biotechnology) that was administered i.p. at 2 mg /kg (in saline) per mouse as reported

(5) The Chemokine Receptor CCR3 Is Potentially Involved in the Homing of Prostate Cancer Cells to Bone: Implication of Bone-Marrow AdipocytesInternational journal of molecular sciencesFebruary 17, 2021Guérard A, Laurent V, Fromont G, Estève D, Gilhodes J, Bonnelye E, Le Gonidec S, Valet P, Malavaud B, Reina N, et al.pharmacological inhibitors: 200nM CCR1/CCR3 inhibitor, UCB35625 (Tocris, Bristol, UK), 25nM CCR2 inhibitor, sc-202525 (Santa Cruz Biotechnology, Dallas, TE, USA), 50nM CXCR1/2 inhibitor, SB225002 (Tocris, Bristol, UK)

(6) Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma CellsBiomedicinesJanuary 4, 2021Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, Nagatakiya M, Katsuyama M, Yamamoto Y, Tsurushima K, et al.

(7) Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapyTheranosticsJanuary 1, 2021Chu CY, Lee YC, Hsieh CH, Yeh CT, Chao TY, Chen PH, Lin IH, Hsieh TH, Shih JW, Cheng CH, et al.

(8) Cytotoxic T cells swarm by homotypic chemokine signallingeLifeOctober 13, 2020Galeano Niño JL, Pageon SV, Tay SS, Colakoglu F, Kempe D, Hywood J, Mazalo JK, Cremasco J, Govendir MA, Dagley LF, et al.(000–22038),(1 µM) "Chemical compound, drug",CCR2 antagonist,Santa Cruz Biotechnology Inc,Cat. #: sc-202525,(1 µM) "Chemical compound, drug",UCB35625 (CCR1 + CCR3 dual inhibitor),R & D Systems,Cat. #: 2757/1,(50

(9) Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasisJCI insightSeptember 17, 2020Xia H, Li S, Li X, Wang W, Bian Y, Wei S, Grove S, Wang W, Vatan L, Liu JR, et al.analyzed. For inhibiting monocyte migration, mice were I.P. injected with 50 μg/kg CCR2 antagonist (sc-202525, Santa Cruz Biotechnology) every other day for 2 weeks. Then pretreated mice were inoculated with 2

(10) Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic CancerCancer discoveryJuly 1, 2020Hou P, Kapoor A, Zhang Q, Li J, Wu CJ, Li J, Lan Z, Tang M, Ma X, Ackroyd JJ, et al.positive control for the chemoattractant assay of BMDMs, and 5 μM CCR2 inhibitor (Santa Cruz biotech, sc-202525) to block the chemotaxis. ChIP-sequencing and ChIP-q-PCR ChIP was performed as describe previously(57).

(11) Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell CarcinomaCancer immunology researchApril 1, 2020Xiang H, Ramil CP, Hai J, Zhang C, Wang H, Watkins AA, Afshar R, Georgiev P, Sze MA, Song XS, et al.

(12) The prognostic value of miRNA-18a-5p in clear cell renal cell carcinoma and its function via the miRNA-18a-5p/HIF1A/PVT1 pathwayJournal of CancerJanuary 1, 2020Wang H, Li ZY, Xu ZH, Chen YL, Lu ZY, Shen DY, Lu JY, Zheng QM, Wang LY, Xu LW, et al.

(13) Ultravist Induces the Expression of MCP-1 and VCAM-1 in IL-4-Stimulated HUVECsBiological & pharmaceutical bulletinJune 1, 2019Kim HL, Kim NS, Cho HY, Park SJ, Lee CK, Choi I, Lee SW.

(14) Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progressionOncogeneJune 1, 2019Bao D, Zhao J, Zhou X, Yang Q, Chen Y, Zhu J, Yuan P, Yang J, Qin T, Wan S, et al.In antagonist treatment group, mice were intraperitoneally injected with 50 mg/kg CCR2 antagonist (sc-202525, Santa Cruz Biotechnology, Santa Cruz, CA) by every other day after tumor cell implantation. One week

(15) CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cellsCancer scienceJanuary 1, 2019Natsagdorj A, Izumi K, Hiratsuka K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Shigehara K, Kadono Y, et al.

(16) Testicular orphan receptor 4 promotes tumor progression and implies poor survival through AKT3 regulation in seminomaCancer ScienceFebruary 4, 2018Yuanlei Chen, Jieyang Lu, Liqun Xia, Dingwei Xue, Xiaoming Yu, Danyang Shen, Liwei Xu, Gonghui LiAntibodies and reagents Anti‐TR4 antibody (ab109301) was purchased from Abcam. Anti‐GAPDH (6c5) antibody (sc‐202525) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti‐AKT1 (ab81283), Anti‐AKT2

(17) p115 RhoGEF activates the Rac1 GTPase signaling cascade in MCP1 chemokine-induced vascular smooth muscle cell migration and proliferationThe Journal of biological chemistryAugust 25, 2017Singh NK, Janjanam J, Rao GN.

(18) Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cellsOncotargetJune 13, 2017An J, Xue Y, Long M, Zhang G, Zhang J, Su H.CCL2 (rhCCL2) was purchased from Pepro Tech (Rocky Hill, NJ, USA), CCR2 antagonist (CAS 445479-97-0, sc-202525) and MMP-9 Inhibitor I (sc-311437) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

(19) Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF InhibitorsCancer researchApril 1, 2017Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, Wood TA, Boni A, Molodtsov A, Angeles CV, et al.µg/dose) antibody was administered i.p. twice weekly, beginning on indicated days. CCR2 antagonist (SC-202525, Santa Cruz Biotechnology) was administered i.p. at 90 µg/dose (in saline + 10% DMSO and 10% Tween80),

(20) The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia CellsPloS oneJanuary 1, 2017Macanas-Pirard P, Quezada T, Navarrete L, Broekhuizen R, Leisewitz A, Nervi B, Ramírez PA.20 mg/ml and was administered at a dose of 5 mg/Kg as a subcutaneous injection. The CCR2 antagonist, SC202525 (Santa Cruz Biotechnology, Dallas, TX) was supplied as a sterile lyophilized powder, soluble in DMSO

Be the First to Write a Review!

CCR2 Antagonist Chemicals

CCR2 Antagonist from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (37)

Reviews

CCR2 Antagonist from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map